in vitro News and Research

RSS

Oral SARS-CoV-2 Mpro inhibitor for therapeutic use

A new study describes a new small molecule compound that has shown impressive safety, tolerability, and bioavailability against SARS-CoV-2.

7 Nov 2021

Convalescent plasma post-vaccination increases binding and neutralizing antibodies against SARS-CoV-2 variants

A recent study assesses the boost in antibodies against SARS-CoV-2)variants post-vaccination in plasma samples from previously infected COVID-19 patients.

7 Nov 2021

Pfizer COVID-19 vaccine elicits durable specific memory T-cell response

A new preprint describes the protective efficacy of memory T-cells developed in response to the viral antigen, which could offer long-term immunity.

4 Nov 2021

Novel model-based framework evaluates immune mechanism of COVID-19 vaccine response

A model framework for characterizing viral dynamics and vaccine efficacy in non-human primates is described and applied to the identification of correlates of protection in three independent vaccine studies.

4 Nov 2021

Adaptive immunity in patients infected with SARS-CoV-2 Δ382 Variant

A comprehensive characterization of the immune responses between SARS-CoV-2 infected individuals with wildtype (WT) and Δ382 SARS-CoV-2.

3 Nov 2021

SARS-CoV-2 neutralizing antibodies discovered in a 20-year-old human antibody library

In an article published in the open-access journal Advance Engineering, a multinational team of researchers reported the selection and characterization of 3 potent SARS-CoV-2 antibodies - S-E6, S-B8, and S-D4 - from a pre-COVID-19 human combinatorial antibody library that was established 20 years ago.

3 Nov 2021

Isolation of potent neutralizing monoclonal antibodies using nanoparticles displaying SARS-CoV-2 S glycoprotein

A new study aimed to identify several potent neutralizing RBD-directed and NTD-directed mAbs that used a nanoparticle displaying the S glycoprotein to capture SARS-CoV-2-specific B cells.

2 Nov 2021

Placental cell-type productively infected with SARS-CoV-2

A new preprint describes the development of a new platform for evaluating the risk of SARS-CoV-2 infection in placental tissue.

2 Nov 2021

Evidence antibodies targeting HCoV-OC43 are robustly boosted in response to SARS-CoV-2 but not vaccination

The magnitude of cross-reactive antibodies correlated well with responses to the SARS-CoV-2 spike protein and the S2 subdomain.

1 Nov 2021

Curcumin, a bioactive component of turmeric, effectively neutralizes SARS-CoV-2 in vitro

The researchers investigated the neutralizing activity of turmeric root extract, curcumin-containing capsules, and pure curcumin against SARS-CoV-2.

1 Nov 2021

Study finds inhaled microspheres reduce SARS-CoV-2 infective effectiveness

A new study develops an inhaled microfluidic microsphere with a genetically engineered membrane from the ACE2 receptor-overexpressing cells and macrophages.

1 Nov 2021

The Connection between High-sensitivity Troponin and Heart Attacks

This interview outlines the connection between high-sensitivity troponin and heart attacks.

From Siemens Healthineers 1 Nov 2021

Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity

A recent study published in the journal Cellular & Molecular Immunology shows that a new A.30 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can evade vaccine-induced antibodies and might spread outside the lungs extraordinarily well, with important implications for our public health response.

1 Nov 2021